Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/8/?d=1Neue Studien: Europe PMCdeFactors influencing quality of life in patients with psoriasis: A large cross-sectional study.https://www.psoriasis-news.de/articles.html/1_articles/factors-influencing-quality-of-life-in-patients-with-psoriasis-a-large-cross-sectional-study-r398/BackgroundPsoriasis is a systemic disease that brings enormous mental pressure and economic burden to patients and has a significant impact on patients' quality of life (QoL). This study aimed to explore factors affecting the dermatology life quality index (DLQI) in patients with psoriasis.

Methods

This retrospective cross-sectional study used data sourced from the Psoriasis Diagnosis and Treatment Real-world Database, and 8839 patients with psoriasis (recruited between June 24, 2020 and September 2, 2021) were included. Demographic and clinical characteristics and DLQI scores were retrospectively analyzed, and correlations between DLQI score and age, disease course, psoriasis area and severity index (PASI) score were calculated. Regression analysis was conducted to explore the factors affecting the DLQI scores of patients with psoriasis.

Results

The average DLQI scores were significantly higher in young (8.58 ± 7.22) and middle-aged individuals (8.09 ± 6.61) than those in juveniles (6.00 ± 5.79) and older individuals (7.39 ± 6.29) (P = 1.70E-15). The average DLQI scores gradually decreased among individuals whose work status were unemployment (10.4 ± 7.83), part-time (9.02 ± 6.83), full-time (8.43 ± 6.90), retired (7.93 ± 6.07), and students (7.10 ± 6.31) (P = 9.82E-23). Except for those with disease course ≥20 years, DLQI scores increased gradually with prolongation of the disease course (P = 4.72E-22). The higher the severity of psoriasis, the higher the average DLQI score (P = 3.79E-113). The presence of psoriatic lesions at the exposed sites significantly affected DLQI scores (P <0.001). The average DLQI scores were significantly higher among individuals with nail holes, joint pain, and comorbidities than among those without these conditions (P <0.05). Correlation analysis indicated that the PASI scores were positively correlated with the DLQI scores (r = 0.26, P = 4.19E-134). Multinomial logistic regression analysis showed significant influencing factors (excluding comorbidity) with different degrees of impact based on the DLQI score (P <0.05).

Conclusion

Physicians should focus on significant factors, such as sex, age, marital status, education, work status, sub-types, disease course, PASI score, without joint pain, and without nail holes, to improve the QoL of patients with psoriasis.

Weiterlesen

]]>398Sat, 27 Dec 2025 18:01:44 +0000Neuroimmune Crosstalk in Psoriasis: Mechanisms and Therapeutic Implications.https://www.psoriasis-news.de/articles.html/1_articles/neuroimmune-crosstalk-in-psoriasis-mechanisms-and-therapeutic-implications-r397/No abstract supplied.

Weiterlesen

]]>397Sat, 27 Dec 2025 18:01:44 +0000Evaluating the Body Roundness Index as a Novel Digital Biomarker for Psoriasis Risk Prediction: Cross-Sectional Study.https://www.psoriasis-news.de/articles.html/1_articles/evaluating-the-body-roundness-index-as-a-novel-digital-biomarker-for-psoriasis-risk-prediction-cross-sectional-study-r396/BackgroundPsoriasis is a chronic inflammatory skin disorder that has been increasingly linked to metabolic imbalances, particularly obesity. Conventional anthropometric indicators such as BMI and waist circumference (WC) may not sufficiently capture body fat distribution or reflect metabolic risk. The body roundness index (BRI), which integrates both height and waist measurements, has emerged as a potentially superior metric, though its relevance to psoriasis risk remains underexplored.

Objective

This study aimed to investigate the use of BRI as a digital biomarker for assessing psoriasis risk and to compare its predictive strength against BMI and WC across various demographic and metabolic subgroups using data from a nationally representative sample.

Methods

A cross-sectional analysis was conducted using data from 13,798 adults aged 20 to 59 years who participated in the National Health and Nutrition Examination Survey between 2003 and 2006 as well as between 2009 and 2014. Psoriasis status was self-reported. Anthropometric measures (BRI, BMI, and WC) were calculated from standardized physical assessments. Weighted multivariable logistic regression models and restricted cubic spline analyses were used to examine associations while adjusting for demographic, metabolic, and lifestyle variables. A nomogram was constructed to quantify the relative predictive contributions of each metric.

Results

BRI exhibited a strong linear association with psoriasis risk (odds ratio [OR] 1.11 per unit increase, 95% CI 1.05-1.17; P<.001), outperforming BMI (OR 1.03) and WC (OR 1.01). Tertile analysis revealed a 1.73-fold increased risk of psoriasis in the highest BRI group (P=.003). Subgroup analyses confirmed consistent associations across age, sex, race or ethnicity, and metabolic status (P for interaction >.05). The nomogram highlighted BRI as the most influential predictor, indicated by its broad scoring range.

Conclusions

BRI shows stronger and more consistent associations with psoriasis risk than BMI or WC, supporting its potential role as a digital biomarker for early risk stratification. Incorporating BRI into clinical decision-making tools may enhance personalized approaches to psoriasis prevention and management.

Weiterlesen

]]>396Sat, 27 Dec 2025 18:01:44 +0000Inflammation mediation of the association between brominated flame retardants and psoriasis among U.S. adultshttps://www.psoriasis-news.de/articles.html/1_articles/inflammation-mediation-of-the-association-between-brominated-flame-retardants-and-psoriasis-among-us-adults-r395/No abstract supplied.

Weiterlesen

]]>395Sat, 27 Dec 2025 18:01:44 +0000Interface-Engineered Nanocarriers for Translational and Patient-Centric Topical Therapy in Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/interface-engineered-nanocarriers-for-translational-and-patient-centric-topical-therapy-in-psoriasis-r394/Weiterlesen

]]>394Sat, 27 Dec 2025 18:01:44 +0000Non-invasive transdermal delivery of peptide inhibitors of the IL-23/IL-17 axis by novel ionic liquid biomaterials for psoriasis treatment.https://www.psoriasis-news.de/articles.html/1_articles/non-invasive-transdermal-delivery-of-peptide-inhibitors-of-the-il-23il-17-axis-by-novel-ionic-liquid-biomaterials-for-psoriasis-treatment-r393/e.g., susceptibility to degradation, large molecular size, hydrophobicity and charge. Herein, we used novel ionic liquid biomaterials, amino acid esters and octanoic acids, as a non-invasive transdermal drug delivery system for bicyclic peptide inhibitors targeted to IL-23R and IL-17A. Using phenotypical images, psoriasis area and severity index, hematoxylin-eosin, and immunohistochemistry, we demonstrate that a biocompatible ionic liquid-based topical delivery approach of peptide inhibitors alleviates psoriasis in an imiquimod-induced psoriasis mouse model. Flow cytometry of innate lymphoid cells (ILCs) within the spleen, peripheral blood, and lesional epidermis shows that treatment with ionic liquids-peptides selectively blocks and reconfigures the spectrum of skin-resident and circulating ILCs. These results provide a framework for a topical delivery approach for peptides. Our findings highlight the potential of topical administration of peptide inhibitors of the IL-23/IL-17 pathway by biocompatible ionic liquids to treat psoriasis. The main immunopathogenic mechanism of peptide inhibitors mitigating psoriasis is reconfiguration of a spectrum of skin-resident and circulating ILCs.

Weiterlesen

]]>393Sun, 21 Dec 2025 14:44:00 +0000Integrative bioinformatics-machine learning-experimental validation identifies shared immunomodulatory targets in psoriasis and psoriatic arthritis and deciphers allicin's therapeutic mechanism.https://www.psoriasis-news.de/articles.html/1_articles/integrative-bioinformatics-machine-learning-experimental-validation-identifies-shared-immunomodulatory-targets-in-psoriasis-and-psoriatic-arthritis-and-deciphers-allicins-therapeutic-mechanism-r392/Weiterlesen

]]>392Sun, 21 Dec 2025 14:44:00 +0000Dietary habits, nutritional supplement use, and adherence to national dietary guidelines in patients with psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/dietary-habits-nutritional-supplement-use-and-adherence-to-national-dietary-guidelines-in-patients-with-psoriasis-r391/Weiterlesen

]]>391Sun, 21 Dec 2025 14:44:00 +0000Impact of weight-loss interventions on psoriasis severity: A systematic review and meta-analysis.https://www.psoriasis-news.de/articles.html/1_articles/impact-of-weight-loss-interventions-on-psoriasis-severity-a-systematic-review-and-meta-analysis-r390/BackgroundPsoriasis affects at least 60 million people worldwide, and 80% also live with overweight or obesity. Excess weight increases susceptibility to psoriasis and is associated with more severe disease.

Objective

To evaluate the impact of weight-loss interventions on psoriasis severity (Psoriasis Area and Severity Index [PASI], PASI50, PASI75, PASI100 [50%/75%/100% reduction in baseline PASI, respectively]) and quality of life (Dermatology Life Quality Index [DLQI]).

Methods

We systematically searched five databases and two trial registries (inception to 03/09/2025). Outcomes were informed by patient focus-group discussions. Randomized controlled trials (RCTs) in adults with psoriasis, comparing any weight-loss intervention versus usual care or a lower-intensity weight-loss intervention, were included. Studies had to report a change in weight and ≥1 psoriasis severity or quality-of-life measure. Random effects meta-analyses were used.

Results

Thirteen RCTs (1145 participants) with 14 comparisons were included. Eleven interventions advised dietary changes, of which four included physical activity. Three used weight-loss medications. Across 14 comparisons (n = 1145, mean difference (MD) in weight change: -6.7 kg), weight-loss interventions produced a greater reduction in PASI versus control: MD -2.5 (95%CI: -3.8 to -1.1, I2 = 85.2%). We found a significant effect of weight-loss interventions on the likelihood of achieving PASI75 (RR = 1.6, 95%CI: 1.1-2.2, I2 = 22.6% [based on six comparisons, n = 681, MD in weight change: -7.3 kg]). There was no statistically significant effect of the interventions on the likelihood of achieving PASI50 (RR = 1.5, 95%CI: 0.9-2.4, I2 = 72.8% [based on four comparisons, n = 509, MD in weight change: -4.0 kg]) or PASI100 (RR = 1.6, 95%CI: 0.3-9.7, I2 = 0.0% [based on two comparisons, n = 334, MD in weight change: -5.2 kg]), but both analyses were limited by few studies. Across seven comparisons (n = 364; MD in weight change -7.8 kg), weight-loss interventions were associated with a significant improvement in DLQI compared to control: MD -5.0 (95%CI: -9.7 to -0.3, I2 = 96.0%).

Conclusion

High-certainty evidence suggests weight-loss interventions can improve psoriasis severity and quality of life, and should be considered as part of routine treatment.

Weiterlesen

]]>390Sun, 21 Dec 2025 14:44:00 +0000Beyond trauma: Schema-driven psychological burden in psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/beyond-trauma-schema-driven-psychological-burden-in-psoriasis-r389/Weiterlesen

]]>389Sun, 21 Dec 2025 14:44:00 +0000Sex-specific associations between nutritional status, disease activity, and fatigue in psoriatic arthritis: a cross-sectional analysis.https://www.psoriasis-news.de/articles.html/1_articles/sex-specific-associations-between-nutritional-status-disease-activity-and-fatigue-in-psoriatic-arthritis-a-cross-sectional-analysis-r388/ObjectiveThe purpose of this study was to evaluate the relationship between nutritional status-assessed by the Controlling Nutritional Status (CONUT) score-and disease activity, fatigue, and sleep quality in patients with psoriatic arthritis (PsA), with attention to sex-specific differences.

Methods

113 adults with PsA were included in this cross-sectional study. Nutritional status was classified as normal (CONUT 0-1) or malnutrition (CONUT ≥ 2). Disease activity was assessed using the Disease Activity in Psoriatic Arthritis (DAPSA) score, fatigue using the Fatigue Severity Scale (FSS), and sleep quality using the Jenkins Sleep Scale (JSS). Correlation and ROC analyses were performed.

Results

Malnutrition was identified in 18.6% of patients. Compared to those with normal nutritional status, malnourished patients had higher CRP (12.8 vs. 6.4 mg/L, p = 0.012) and lower albumin and lymphocyte levels (p < 0.001). High disease activity (DAPSA > 28) was more common in the malnutrition group (38.1% vs. 15.2%, p = 0.029). The CONUT score correlated with DAPSA (Rho = 0.327, p < 0.001), CRP (Rho = 0.422, p < 0.001), and fatigue severity (Rho = 0.186, p = 0.048). No association was observed with sleep quality. ROC analysis showed that CONUT ≥ 2 predicted high disease activity (AUC 0.70). In sex-stratified analyses, correlations with DAPSA and fatigue were present only in females.

Conclusion

Higher CONUT scores were associated with greater disease activity and fatigue among patients with psoriatic arthritis. These results underscore the potential value of incorporating routine nutritional evaluation into the comprehensive management of PsA.

Weiterlesen

]]>388Sun, 21 Dec 2025 14:44:00 +0000The Inverse Association of Psoriasis and Life's Crucial 9 in US Adults: An Analysis from NHANES.https://www.psoriasis-news.de/articles.html/1_articles/the-inverse-association-of-psoriasis-and-lifes-crucial-9-in-us-adults-an-analysis-from-nhanes-r387/BackgroundLife's Crucial 9 (LC9) is a new tool used to evaluate cardiovascular health. At present, no studies have reported the association between LC9 and psoriasis.

Methods

This cross-sectional study utilized data from the National Health and Nutrition Examination Survey (NHANES) conducted between 2009 and 2014. The LC9 score was calculated based on the American Heart Association's recommendations and the Patient Health Questionnaire-9 assessment. Psoriasis status was identified using self-reported questionnaires. Weighted multivariable logistic regression and restricted cubic splines were applied to assess the association between LC9 and psoriasis. Subgroup analyses were conducted for each covariate, and the interaction between LC9 and potential confounders was examined. Additionally, sensitivity analyses were performed to assess the robustness of the results.

Results

A total of 11,762 participants aged 20 years and older were included in this study. After comprehensive adjustments, a negative linear association was observed between psoriasis and LC9: Each 10-point increment in LC9 corresponded to an odds ratio (OR) of 0.87 (95% CI: 0.78-0.96) for psoriasis. Relative to participants in the lowest LC9 quartile (Q1), the ORs for psoriasis were 0.73 (95% CI: 0.55-0.96) for Q3 and 0.55 (95% CI: 0.36-0.85) for Q4. Among participants aged 45 to 64 years, those in the highest LC9 quartile (Q4) had an adjusted OR of 0.42 (95% CI: 0.23-0.78). Heavy drinkers in Q4 exhibited an adjusted OR of 0.37 (95% CI: 0.15-0.92). Sensitivity analyses confirmed these results.

Conclusion

A linear negative relationship between psoriasis and LC9 was identified in this study. This observational result suggesting that enhancing LC9-related cardiovascular health factors may serve as an effective approach for psoriasis prevention and management.

Weiterlesen

]]>387Sun, 21 Dec 2025 14:44:00 +0000Increased Risk of Hematologic Malignancy in Moderate to Severe Psoriasis in Relation to the Use of Systemic Immunosuppressants: A Nationwide Population-Based Matched Cohort Study.https://www.psoriasis-news.de/articles.html/1_articles/increased-risk-of-hematologic-malignancy-in-moderate-to-severe-psoriasis-in-relation-to-the-use-of-systemic-immunosuppressants-a-nationwide-population-based-matched-cohort-study-r386/BackgroundThe relationship between cancer and the use of systemic immunosuppressants in psoriasis treatment has not well established. The aim of this study was to evaluate the association between the systemic immunosuppressants used in the treatment for psoriasis and the risk of certain cancers in Korean patients with moderate to severe psoriasis.

Methods

A retrospective cohort study was conducted involving 93,152 patients with moderate to severe psoriasis and 205,850 matched controls in Korea, using merged data from the National Health Insurance System, Health Insurance Review & Assessment Service, and Korea National Cancer Incidence Database from 2008 to 2018.

Results

The study observed a lower incidence of any cancer in moderate to severe psoriasis patients (2.4%) compared to the general population (2.99%). However, there was a higher risk of hematologic cancers, particularly Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, and cutaneous T cell lymphoma. Notably, methotrexate doses of ≥ 17.5 mg/week increased the risk of hematologic cancer risk by 7.546 times and cutaneous T cell lymphoma risk by 9.038 times, but cyclosporine and corticosteroids use did not show a significant association with increased incidence of hematologic cancers. Meanwhile, use of cyclosporine, methotrexate and corticosteroid did not significantly affect the risk of skin cancer among patients with psoriasis.

Conclusion

This study reveals an increased risk of hematologic cancers, such as cutaneous T cell lymphomas, associated with high-dose immunosuppressant use in moderate to severe psoriasis, underscoring the need for careful treatment management.

Weiterlesen

]]>386Sun, 21 Dec 2025 14:44:00 +0000Evaluation of netrin 1 as a new biomarker in the differentiation of psoriatic arthritis from psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/evaluation-of-netrin-1-as-a-new-biomarker-in-the-differentiation-of-psoriatic-arthritis-from-psoriasis-r385/Weiterlesen

]]>385Sun, 21 Dec 2025 14:44:00 +0000Establishment of the Kenyan Psoriasis Registry: A Case-Control Cohort.https://www.psoriasis-news.de/articles.html/1_articles/establishment-of-the-kenyan-psoriasis-registry-a-case-control-cohort-r384/IntroductionPsoriasis is a chronic inflammatory skin disease with a global prevalence of 1-5%, however its clinical and demographic profile in Kenya remains underexplored. This article describes the establishment of the Kenyan Psoriasis Registry at Moi Teaching and Referral Hospital in Eldoret, Kenya.

Methods

214 subjects were enrolled between October 2024 and August 2025 at Moi Teaching and Referral Hospital. Both healthy controls and patients with psoriasis completed enrollment surveys and physical exams, and donated saliva samples.

Results

The initial cohort of 214 subjects (108 patients with psoriasis, 106 healthy controls) provides valuable insights into the demographics, clinical profiles, quality of life, and mental health characteristics of patients with psoriasis in Kenya. The mean age of psoriasis onset was 30.4 years, and mean age of diagnosis by a medical provider was 38.9 years old. 13.9% of patients with psoriasis reported a positive family history of psoriasis, and 9.3% of patients with psoriasis reported a diagnosis of psoriatic arthritis. The mean psoriasis area and severity index was 9.9 and mean Investigator Global assessment score was 3.0. Examination of treatment patterns revealed that moisturizers, prescription topical medications, and methotrexate were commonly tried while only 9.3% of individuals had ever received a biologic therapy. Patients with psoriasis reported significantly worse sleep disturbance, quality of life, and mental health compared to healthy controls.

Conclusion

This data highlights the unique characteristics of patients with psoriasis in Kenya. The Kenyan Psoriasis Registry continues to enroll patients and conduct yearly follow-ups, aiming to deepen the understanding of psoriasis in this population. These findings underscore the need for targeted research and advocacy to improve psoriasis care in Kenya.

Weiterlesen

]]>384Sun, 21 Dec 2025 14:44:00 +0000Association between the Frailty Index and psoriasis: a cross-sectional study of the U.S. NHANES 2003-2006.https://www.psoriasis-news.de/articles.html/1_articles/association-between-the-frailty-index-and-psoriasis-a-cross-sectional-study-of-the-us-nhanes-2003-2006-r379/BackgroundPsoriasis is a chronic inflammatory skin disease often accompanied by various comorbidities, but its relationship with frailty remains understudied. The Frailty Index (FI), calculated based on 49 health deficits across multiple systems (e.g., cognition, function, comorbidities, laboratory values) was used as a continuous measure.

Objectives

We investigated the association between psoriasis and the Frailty Index (FI), providing evidence to support the implementation of frailty screening and potential interventions in patients with psoriasis.

Design and setting

This cross-sectional study used data from the 2003-2006 U.S. National Health and Nutrition Examination Survey (NHANES) including 6532 participants.

Measurements

We analyzed the psoriasis-FI relationship using weighted nested regression, supplemented by subgroup analyses and restricted cubic spline regression to test for nonlinear relationships.

Results

The FI was significantly higher in patients with psoriasis (n = 162) than in those without (n = 6370; P < 0.001). Weighted nested regression analysis showed a significant positive association between FI and psoriasis (OR 2.22; 95% CI 1.14-4.35; P = 0.02). The association was stronger for male patients, those with normal body mass index, hypertension, and diabetes. Nonlinear relationships were observed between FI and psoriasis.

Conclusions

The present study validates the association between psoriasis and frailty using a nationally representative sample and provides empirical support for integrating frailty evaluations into psoriasis care. Our findings are consistent with the hypothesis that chronic inflammatory pathways may underlie the association between psoriasis and frailty.

Weiterlesen

]]>379Thu, 18 Dec 2025 08:21:10 +0000Perforating dermatosis in a young female patient receiving adalimumab biosimilar CTP-17 for chronic plaque psoriasis: A case report.https://www.psoriasis-news.de/articles.html/1_articles/perforating-dermatosis-in-a-young-female-patient-receiving-adalimumab-biosimilar-ctp-17-for-chronic-plaque-psoriasis-a-case-report-r378/Weiterlesen

]]>378Thu, 18 Dec 2025 08:21:10 +0000Therapeutic mechanism of Pithecellobium clypearia Benth. on imiquimod-induced psoriasis revealed by tissue transcriptomics in mice.https://www.psoriasis-news.de/articles.html/1_articles/therapeutic-mechanism-of-pithecellobium-clypearia-benth-on-imiquimod-induced-psoriasis-revealed-by-tissue-transcriptomics-in-mice-r377/BackgroundPsoriasis is an erythema papulosquamous dermatosis that cannot be cured at present. Pithecellobium clypearia Benth. belonging to the Leguminosae family and is clinically used as a treatment for gastroenteritis, acute tonsillitis, acute pharyngitis, and upper respiratory tract infections. Our previous studies have found that P. clypearia can improve imiquimod (IMQ)-induced psoriasis in mice and have revealed some differential metabolites and pathways using metabolomics methods. However, the underlying molecular mechanisms remain obscure. The purpose of this study is to investigate the therapeutic mechanism of the anti-psoriatic effects of P. clypearia using transcriptomics technology.

Methods

The psoriasis model was induced in male Balb/c mice by applying IMQ on their backs. To identify the differentially expressed genes (DEGs) among groups, RNA sequencing was employed. DEGs were analyzed using Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and protein-protein interaction (PPI) network analysis. Furthermore, quantitative real-time PCR (qPCR) was employed for validation of these results.

Results

A total of 26 DEGs were identified, with several enriched pathways, including the MAPK signaling pathway, unfolded proteins response, hedgehog signaling pathways, NADH dehydrogenase activity, oxidative phosphorylation. Additionally, PPI network analysis revealed that gene Hspa1a was connected with Hspa1b, Bcl2 and GzmA, and Asns was related to Trib3, Slc7a5 and Chac1, and mt-Nd4l was correlated with mt-Nd5 and mt-Nd6. The RNA-seq results were concordant with the qPCR results.

Conclusions

P. clypearia may ameliorate inflammation in psoriasis mice by modulating genes such as Hspa1a, Hspa1b, mt-Nd4l, mt-Nd5, mt-Nd6, Bcl2, Asns, Trib3, and associated pathways related to energy metabolism, cell growth, and apoptosis. Our study explored the underlying molecular mechanisms at the transcriptome level and provided a theoretical basis for further investigation into the efficacy of P. clypearia.

Weiterlesen

]]>377Thu, 18 Dec 2025 08:21:10 +0000Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year.https://www.psoriasis-news.de/articles.html/1_articles/bimekizumab-efficacy-and-safety-in-patients-with-psoriatic-arthritis-with-substantial-skin-and-nail-psoriasis-to-1%C2%A0year-r376/IntroductionIndividuals with psoriatic arthritis (PsA) and plaque-type psoriasis and nail involvement have more severe disease and worse quality of life than those without. Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. Here, we assess 52-week efficacy and safety of bimekizumab in individuals with PsA who had baseline plaque-type psoriasis (≥ 3% body surface area) and nail involvement (modified Nail Psoriasis Severity Index [mNAPSI] > 0).

Methods

We conducted a post hoc analysis of BE OPTIMAL (NCT03895203; biologic disease-modifying antirheumatic drug [biologic]-naïve patients) and BE COMPLETE/BE VITAL open-label extension (NCT03896581/NCT04009499; patients with prior inadequate response/intolerance to tumour necrosis factor inhibitors [TNFi-IR]). Participants were randomised to subcutaneously administered bimekizumab 160 mg every 4 weeks (Q4W), placebo or reference arm (adalimumab 40 mg Q2W; BE OPTIMAL only). At week 16, placebo-randomised participants switched to bimekizumab (PBO/BKZ). Participants who completed BE COMPLETE week 16 could enter BE VITAL. Efficacy and safety data are reported by study to week 52. Efficacy outcomes included American College of Rheumatology ≥ 50% improvement (ACR50), Psoriasis Area and Severity Index 100% improvement (PASI100) and nail psoriasis resolution (mNAPSI = 0).

Results

Overall, 263 (placebo n = 88; bimekizumab n = 133; reference [adalimumab] n = 42) biologic-naïve and 159 (placebo n = 54; bimekizumab n = 105) TNFi-IR participants had baseline plaque-type psoriasis and nail involvement. In bimekizumab-randomised participants with baseline plaque-type psoriasis and nail involvement, improvements in the proportion of participants achieving efficacy responses across disease domains were sustained from week 16 to week 52, including ACR50 (65.4% biologic-naïve; 61.0% TNFi-IR), PASI100 (60.9%; 63.8%), and mNAPSI = 0 (68.4%; 70.5%). PBO/BKZ switchers demonstrated improvements from week 16 to week 52 after receiving 36 weeks of bimekizumab treatment, for ACR50 (63.6% biologic-naïve; 51.9% TNFi-IR), PASI100 (64.8%; 57.4%), and mNAPSI = 0 (73.9%; 63.0%). To week 52, exposure-adjusted incidence rates/100 patient years for ≥ 1 treatment-emergent adverse event in all bimekizumab-treated (≥ 1 dose) participants with baseline plaque-type psoriasis and nail involvement were 181.1 (biologic-naïve) and 99.2 (TNFi-IR).

Conclusions

Bimekizumab treatment resulted in consistent, sustained efficacy to 52 weeks in biologic-naïve and TNFi-IR individuals with PsA and baseline plaque-type psoriasis and nail involvement. Bimekizumab was well tolerated, with a safety profile consistent with previous reports. Graphical abstract available for this article.

Trial registration

BE OPTIMAL: NCT03895203; BE COMPLETE: NCT03896581; BE VITAL: NCT04009499 (ClinicalTrials.gov).

Weiterlesen

]]>376Thu, 18 Dec 2025 08:21:10 +0000Global Research Trends in Apremilast for Psoriasis: A Bibliometric Analysis (2008-2024).https://www.psoriasis-news.de/articles.html/1_articles/global-research-trends-in-apremilast-for-psoriasis-a-bibliometric-analysis-2008-2024-r375/PurposePsoriasis is a chronic, immune-mediated skin disease that significantly affects patients' quality of life. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, has emerged as a promising treatment for moderate to severe psoriasis, offering an alternative to biologics with a favorable safety profile. This study analyzes global research trends, key contributors, and emerging focus areas concerning apremilast in the treatment of psoriasis.

Patients and methods

Publications related to apremilast and psoriasis from 2008 to 2024 were retrieved from the Web of Science Core Collection (WoSCC). Bibliometric and visual analyses were performed using tools such as VOSviewer, CiteSpace, and R 4.3.3.

Results

A total of 437 publications on apremilast and psoriasis were identified. The United States led with 158 publications, followed by Japan with 39 and Italy with 33. Celgene Corporation was the most productive institution, contributing 96 articles. The top journals include Journal of Dermatology, Journal of the European Academy of Dermatology and Venereology, and Journal of the American Academy of Dermatology. Key researchers, such as Shinichi Imafuku and Bruce Strober, were identified as leading contributors. Burst analysis revealed that since 2020, keywords like "monotherapy", "nail psoriasis", and "pathogenesis" have gained prominence, indicating emerging research areas.

Conclusion

This bibliometric analysis demonstrates that research on Apremilast for psoriasis has evolved from clinical trials focused on efficacy and safety to broader applications in real-world settings, including nail psoriasis and pathogenesis. Future research is likely to concentrate on long-term outcomes, optimizing treatment regimens, and addressing unmet needs in psoriasis management, particularly among specific patient subgroups.

Weiterlesen

]]>375Thu, 18 Dec 2025 08:21:10 +0000Tildrakizumab in real-world Chinese psoriasis: efficacy-safety profiles from a 28-week retrospective cohort with geriatric, late-onset and metabolic syndrome stratification.https://www.psoriasis-news.de/articles.html/1_articles/tildrakizumab-in-real-world-chinese-psoriasis-efficacy-safety-profiles-from-a-28-week-retrospective-cohort-with-geriatric-late-onset-and-metabolic-syndrome-stratification-r374/ObjectiveTo assess the real-world efficacy and safety of tildrakizumab in Chinese patients with psoriasis stratified by age, age of psoriasis onset and MetS status.

Methods

This two-center retrospective cohort study evaluated tildrakizumab's efficacy and safety over 28 weeks in 80 Chinese adults with moderate-to-severe plaque psoriasis, with subgroup analyses by age and age of psoriasis onset and metabolic syndrome (MetS).

Results

Mean PASI scores showed progressive improvement, declining from 9.3 ± 5.1 at baseline to 1.0 ± 1.4 at week 28 (p < 0.001). A high proportion of patients responded by week 16 (78.4% achieving PASI ≤ 3; 48.6% PASI ≤ 1), with further improvement at week 28 (88.6% and 62.0%, respectively). Dermatology Life Quality Index (DLQI) scores paralleled clinical gains, decreasing from 7.7 ± 4.6 to 0.9 ± 1.8 (p < 0.001), reflecting an 88.3% reduction in quality-of-life impairment. Geriatric patients showed superior PASI 100 responses (81.8% vs 38.6%, p < 0.001) while late-onset patients also represented higher PASI 90 responses (81.5% vs 55.8%, p = 0.027) at week 28. The MetS status did not affect therapeutic response (PASI 100 response: 52.6% vs 45.5%, p = 0.622) at week 28. Safety monitoring identified 4 (5.0%) treatment-emergent adverse events, with no treatment discontinuation for psoriasis exacerbation.

Conclusion

Tildrakizumab demonstrated sustained efficacy in real-world management of moderate-to-severe psoriasis and supported broad applicability across diverse psoriasis subtypes.

Weiterlesen

]]>374Thu, 18 Dec 2025 08:21:10 +0000Dramatic clearance of extensive psoriasis in a pediatric patient treated with upadacitinib: A case report.https://www.psoriasis-news.de/articles.html/1_articles/dramatic-clearance-of-extensive-psoriasis-in-a-pediatric-patient-treated-with-upadacitinib-a-case-report-r373/Weiterlesen

]]>373Thu, 18 Dec 2025 08:21:10 +0000Commentary: Clinical characteristics and influencing factors of cardiovascular comorbidities in psoriasis—a critical appraisal of causality and shared pathogenesishttps://www.psoriasis-news.de/articles.html/1_articles/commentary-clinical-characteristics-and-influencing-factors-of-cardiovascular-comorbidities-in-psoriasisa-critical-appraisal-of-causality-and-shared-pathogenesis-r372/No abstract supplied.

Weiterlesen

]]>372Thu, 18 Dec 2025 08:21:10 +0000Apremilast, Methotrexate and NB-UVB Phototherapy for Moderate to Severe Psoriasis: Efficacy, Safety, and Immunomodulation in Comparison.https://www.psoriasis-news.de/articles.html/1_articles/apremilast-methotrexate-and-nb-uvb-phototherapy-for-moderate-to-severe-psoriasis-efficacy-safety-and-immunomodulation-in-comparison-r371/BackgroundSelecting the most appropriate therapy for psoriasis remains challenging due to variability in disease severity and individual patient factors. Among non-biological treatments, methotrexate (MTX), apremilast (APRE), and narrowband UVB (NB-UVB) phototherapy are widely utilized.

Objective

To compare, under real-world conditions, the clinical efficacy, quality of life, patient satisfaction, and immunomodulatory effects of APRE, MTX, and NB-UVB in moderate-to-severe plaque psoriasis over 16 weeks.

Methods

This pilot prospective observational cohort study included 37 patients treated independently with APRE (n = 13), MTX (n = 15), or NB-UVB (n = 9). Clinical outcomes were assessed using PASI, BSA, PGA, DLQI scores, and the TSQM-9 questionnaire. Systemic and local inflammation were assessed by multiplex cytokine assays and RT-PCR in vivo and in vitro.

Results

By Week 16, significant improvements were observed in PASI, DLQI, and PGA scores across all groups, with no statistically significant differences in efficacy between treatments. A trend toward a greater response was observed for both MTX and APRE. APRE treatment demonstrated a tendency for more pronounced modulation of pro-inflammatory cytokines compared to both MTX and NB-UVB. NB-UVB increased the anti-inflammatory IL-10. Combination therapy with NB-UVB and APRE further increased IL-10 levels and reduced IL-33 in HaCaT cells, suggesting synergistic immunomodulatory effects; however, the clinical relevance of these in vitro findings remains unproven and requires further investigation.

Conclusion

APRE, MTX, and NB-UVB each improved clinical outcomes with comparable overall efficacy and good tolerability in this pilot cohort. Each therapeutic regime showed distinct immunomodulatory profiles with good tolerability. Personalized treatment strategies, including potential combinations, may optimize outcomes for patients with moderate-to-severe psoriasis.

Weiterlesen

]]>371Thu, 18 Dec 2025 08:21:10 +0000The (in)visible cloak: How intersecting stigmas associated with mental and chronic physical disease shape perceptions in a healthcare setting.https://www.psoriasis-news.de/articles.html/1_articles/the-invisible-cloak-how-intersecting-stigmas-associated-with-mental-and-chronic-physical-disease-shape-perceptions-in-a-healthcare-setting-r370/ObjectivesMental illness stigma is widely examined in healthcare, yet less is known about its intersections with the stigma of chronic physical conditions in shaping distinct forms of disadvantage. Here, we investigate whether patients with concurrent mental and physical health conditions are perceived and treated differently by prospective medical doctors.

Methods

Using a mixed-methods design, preclinical medical students (N = 463) evaluated clinical vignettes describing patients with single (i.e., mental or physical chronic disease) and multiple health conditions (i.e., concurrent mental and physical conditions). We assessed emotional reactions, attributions of disease aetiology, caregiving attitudes and meta-beliefs about patients' disclosure behaviour. Participants were also asked to report as accurately as possible on symptoms presented by each patient in the vignette.

Results

Findings revealed that stigmatized conditions were associated with higher levels of caregiving discomfort, greater disease disclosure reticence and lower levels of symptom recall accuracy. Compared with patients with single conditions, those with concurrent mental and physical illnesses were less likely to receive care, were attributed a lesser tendency to conceal their conditions and had their symptoms recalled less accurately.

Conclusions

Results indicate that when mental and physical illnesses intersect, patients with multiple stigmatized conditions may be differentially perceived in the eyes of medical students and may become (in)visible targets of discrimination in a healthcare setting. We discuss implications for enhancing awareness of social determinants of health and disease for a more representative, responsive and inclusive healthcare curriculum and practice.

Weiterlesen

]]>370Thu, 18 Dec 2025 08:21:10 +0000